Adventitial fibroblast (AF)

Adventitial fibroblasts are the predominant cell type within the tunica adventitia, the outermost layer of the vascular wall, where they primarily function to maintain structural integrity by synthesizing extracellular matrix (ECM) components like collagen and elastin (Source: [1], [4]). While quiescent under homeostatic conditions, these cells act as dynamic sensors of vascular stress and injury, undergoing a phenotypic transition into activated myofibroblasts characterized by increased proliferation, migration, and the expression of contractile proteins like alpha-smooth muscle actin (Source: [2], [14]). This activation plays a pivotal role in the pathogenesis of vascular diseases, including atherosclerosis, hypertension, and aortic aneurysms, by driving pathological remodeling and promoting the recruitment of inflammatory cells through the secretion of cytokines such as IL-6 (Source: [3], [9]). Therapeutic interest in adventitial fibroblasts focuses on inhibiting their transformation and fibrotic activity using agents that target signaling pathways such as TGF-beta and Angiotensin II (Source: [10], [12]). Consequently, they are viewed as a critical "outside-in" regulator of vascular health and a promising niche for site-specific drug delivery in cardiovascular medicine (Source: [3], [15]).

Other names

Vascular adventitial fibroblastPerivascular fibroblastTunica adventitia fibroblastPulmonary artery adventitial fibroblast (PAAF)Adventitial myofibroblast

Inhibition of TGF-beta signaling; Blockade of Angiotensin II Type 1 (AT1) receptors; Suppression of myofibroblast differentiation; Reduction of collagen synthesis and ECM deposition; Inhibition of pro-inflammatory cytokine release (e.g., IL-6).